NCT06049810View on ClinicalTrials.gov

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

566

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

April 29, 2025

Study Completion Date

July 28, 2025

Conditions
Psoriasis
Interventions
DRUG

IBI112

Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44

DRUG

IBI112/placebo

Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection

DRUG

IBI112/placebo

Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44

DRUG

IBI112

Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44

DRUG

IBI112

Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44

DRUG

IBI112

Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection

Trial Locations (1)

200443

Shanghai Skin Disease Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06049810 - IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment | Biotech Hunter | Biotech Hunter